Bylvay denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applied a Quantity Limit to Bylvay

Blue Cross Blue Shield routinely applies quantity limits to specialty drugs like Bylvay (odevixibat) to align coverage with the FDA-approved dosing range and the patient's documented weight or clinical parameters. A quantity-limit denial typically means either that the quantity requested on the prescription exceeds what BCBS's policy allows for the approved dose range, or that the dose your prescriber requested cannot be verified against the submitted clinical data. These denials are almost always resolvable with additional documentation.

## Why It Is Appealable

The FDA-approved prescribing information defines the lawful dose range for Bylvay. If your prescriber's prescribed quantity is consistent with the label and with your clinical parameters, BCBS's quantity limit cannot override that on a medical-necessity basis. Your rights:

• ACA §2719 / ERISA §503: Full internal appeal plus independent external review.
• External review window: Generally four months from the final internal denial — confirm the exact deadline on your Explanation of Benefits.
• Expedited review: Available for urgent clinical situations; decisions typically required within 72 hours.

## Appeal Process and Timeline

1. Request the denial in writing with the specific quantity limit BCBS is applying and the policy basis for it. 2. Have your prescriber verify that the prescribed quantity is consistent with the FDA-approved prescribing information for your clinical parameters (without stating specific numbers here — your prescriber and the label itself are the authoritative sources). 3. Submit a quantity-limit exception request with supporting clinical documentation. 4. If denied, file a formal internal appeal within the deadline on the denial notice. 5. Escalate to external review if needed.

## Documentation to Gather

• Current weight and clinical parameters: Recent measurements from the chart, as Bylvay dosing is weight-based per the FDA label — your prescriber must document that the requested quantity corresponds to the label-specified dose for your patient's parameters.
• FDA prescribing information: Printout of the dosing section from the current FDA-approved label, confirming the prescribed quantity falls within approved parameters.
• Prescriber justification letter: A statement that the quantity requested is necessary to deliver the FDA-approved dose for the patient's current clinical parameters, citing the label and the BCBS policy criteria.
• Diagnosis and severity documentation: Chart notes confirming the underlying condition, because quantity-limit exceptions often require re-establishing medical necessity as part of the same submission.

## Criteria-Mapping Structure

For a quantity-limit appeal, the mapping is straightforward: (1) BCBS's stated limit, (2) the FDA label's approved dose range for the patient's documented parameters, (3) the prescriber's calculation linking the two. Document each element specifically and the reviewer will have no clinical basis to sustain the limit.